In October of 2011, Ansun replaced its then Board of Directors with a new slate of Board
members and appointed new management, including Dr. Ronald Moss, who has been Ansun’s
CEO since then. Ansun has made significant progress in the development of therapies for
diseases caused by common viruses such as influenza and parainfluenza. “We continue to work
with leaders in the medical community to develop therapies for unmet medical need. Our
investigational drugs for influenza and parainfluenza are in late stage clinical development. It is
very clear based on the current influenza epidemic that more therapies are urgently needed and
Ansun is committed to developing these therapies for patients,” said Dr. Moss. In September of
2012, Ansun received a contract from the Biomedical Advanced Research and Development
Authority in the amount of $26,500,000 to continue development of Fludase®, its lead
compound for treatment of the flu. Ansun’s pipeline consists of Fludase®, and Paradase™ both
of which are in human clinical trials.
Fludase®, a broad spectrum investigational antiviral biologic has completed phase 2 studies and
is ready for the last stage of clinical development. In studies conducted with the CDC, Fludase
has shown broad activities against many strains of influenza including the circulating strains of
the current influenza epidemic and the H5N1 strain of bird flu, which has a significantly high
mortality rate in infected humans..
Its experimental biologic Paradase is also in human clinical trials. “With Paradase, we are
currently enrolling a phase 2 study in cancer and transplant patients infected with a deadly virus
called parainfluenza,” stated Dr. Moss. Infection with this virus in these patients with
suppressed immune systems is high and there are no current treatments available. “In addition to
enrolling the phase 2 study, Ansun has provided Paradase for parainfluenza to over 70 dying
transplant and leukemic patients under emergency use requests from physicians across the
United States,” explained Dr. Moss.
“We are very pleased that the investigation has been resolved. It never changed our focus, but
now with the investigation behind us, we feel a renewed energy to develop novel and effective
tools to provide the U.S. government and the public potential therapies for the defense against
viruses that affect public health and welfare,” said Dr. Moss.
